Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from BioVersys AG ( (CH:BIOV) ) is now available.
BioVersys AG reported that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting, including the 2025 Annual Report and related financial statements. Investors also backed the proposed compensation limits for the Board and Executive Committee, underscoring continued support for the company’s strategic and financial direction.
The meeting confirmed the re-election of Chairman Seng Chin Mah and four other directors, while appointing industry executive Simona Skerjanec to the Board in place of outgoing member William Jenkins. The outcome reinforces governance continuity as BioVersys advances its late-stage BV100 Phase 3 program and progresses alpibectir and its preclinical pipeline addressing high unmet needs in resistant bacterial infections.
The most recent analyst rating on (CH:BIOV) stock is a Buy with a CHF40.00 price target. To see the full list of analyst forecasts on BioVersys AG stock, see the CH:BIOV Stock Forecast page.
More about BioVersys AG
BioVersys AG is a Basel-based, multi-asset clinical-stage biopharmaceutical company specializing in novel antibacterial products for serious life-threatening infections caused by multi-drug resistant bacteria. Leveraging its TRIC and Ansamycin Chemistry platforms, the company targets antimicrobial and microbiome indications, with lead programs BV100 for Acinetobacter baumannii in Phase 3 and alpibectir for tuberculosis in Phase 2 alongside partners including GSK and academic consortia.
Average Trading Volume: 2,832
Technical Sentiment Signal: Buy
Current Market Cap: CHF172.5M
For an in-depth examination of BIOV stock, go to TipRanks’ Overview page.